Antibody against human prostaglandin E2 receptor EP4
US11649281B2 · kind B2 · utility
0Cited by
1References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 29, 2019 |
| Grant date | May 16, 2023 |
| Priority date | — |
| Expiry date | Aug 30, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.